Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S John

Showing results (1101-1110 of 1,133) with videos related to

Pageof 114
Sort By:
Cell Reports. Medicine|January 14, 2022
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancerDongqing Huang, Shrabanti Chowdhury, Hong Wang, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 8, 2025
Paediatric pulmonary arterial hypertension following congenital heart defect repair: Enhanced risk stratification and outcomes in a national cohortAndrew Constantine, Konstantinos Dimopoulos, Robin Condliffe, et al.
Cancer Research|February 19, 2021
GAS7 Deficiency Promotes Metastasis in MYCN-Driven NeuroblastomaZhiwei Dong, Kok Siong Yeo, Gonzalo Lopez, et al.
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Blueprinting expandable nanomaterials with standardized protein building blocksTimothy F Huddy, Yang Hsia, Ryan D Kibler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Cancer Research|October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with EribulinGwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|September 21, 2020
Characteristics of a Diverse Cohort of Stroke Patients with SARS-CoV-2 and Outcome by SexG Trifan, F D Goldenberg, F Z Caprio, et al.
European Heart Journal|August 30, 2025
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndromeSaranda Nimani, Sahej Bains, Nicolò Alerni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Pageof 114

Showing results (1101-1110 of 1,133) with videos related to

Sort By:
Pageof 114
Cell Reports. Medicine|January 14, 2022
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancerDongqing Huang, Shrabanti Chowdhury, Hong Wang, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 8, 2025
Paediatric pulmonary arterial hypertension following congenital heart defect repair: Enhanced risk stratification and outcomes in a national cohortAndrew Constantine, Konstantinos Dimopoulos, Robin Condliffe, et al.
Cancer Research|February 19, 2021
GAS7 Deficiency Promotes Metastasis in MYCN-Driven NeuroblastomaZhiwei Dong, Kok Siong Yeo, Gonzalo Lopez, et al.
Cancer Research|July 29, 2021
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Olga Kondrashova, Rachel M Hurley, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Blueprinting expandable nanomaterials with standardized protein building blocksTimothy F Huddy, Yang Hsia, Ryan D Kibler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Cancer Research|October 7, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with EribulinGwo Yaw Ho, Elizabeth L Kyran, Justin Bedo, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|September 21, 2020
Characteristics of a Diverse Cohort of Stroke Patients with SARS-CoV-2 and Outcome by SexG Trifan, F D Goldenberg, F Z Caprio, et al.
European Heart Journal|August 30, 2025
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndromeSaranda Nimani, Sahej Bains, Nicolò Alerni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Pageof 114